HC Wainwright & Co. Downgrades ChemoCentryx to Neutral, Lowers Price Target to $52
Benzinga Newsdesk 4 years ago
NewsDowngradesPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Edward White downgrades ChemoCentryx (NASDAQ:CCXI) from Buy to Neutral and lowers the price target from $101 to $52.
HC Wainwright & Co. analyst Edward White downgrades ChemoCentryx (NASDAQ:CCXI) from Buy to Neutral and lowers the price target from $101 to $52.